





























N -Acetylcysteine improves mitochondrial function and
ameliorates behavioral deficits in the R6/1 mouse model of
Huntington's disease
DJWright1,2, T Renoir1, ZM Smith3, AEFrazier4,5, PSFrancis3, DRThorburn4,5,6, SL McGee7,8, AJ Hannan1,9,10 and LJ Gray1,2,10
Huntington’s disease (HD) is a neurodegenerative disorder, involving psychiatric, cognitive and motor symptoms, caused by a
CAG-repeat expansion encoding an extended polyglutamine tract in the huntingtin protein.Oxidative stressand excitotoxicity have
previously been implicated in the pathogenesisof HD.We hypothesized that N-acetylcysteine (NAC)may reduce both excitotoxicity
and oxidative stress through its actions on glutamate reuptake and antioxidant capacity. The R6/1 transgenic mouse model of HD
was used to investigate the effects of NACon HD pathology. It was found that chronic NACadministration delayed the onset and
progression of motor deficits in R6/1 mice, while having an antidepressant-like effect on both R6/1 and wild-type mice. A deficit in
the astrocytic glutamate transporter protein, GLT-1, was found in R6/1 mice. However, this deficit was not ameliorated by NAC,
implying that the therapeutic effect of NAC is not due to rescue of the GLT-1 deficit and associated glutamate-induced
excitotoxicity. Assessment of mitochondrial function in the striatum and cortex revealed that R6/1 mice show reduced
mitochondrial respiratory capacity specific to the striatum. This deficit was rescued by chronic treatment with NAC. There was a
selective increase in markers of oxidative damage in mitochondria, which was rescued by NAC. In conclusion, NACis able to delay
the onset of motor deficits in the R6/1 model of Huntington’s disease and it may do so by ameliorating mitochondrial dysfunction.
Thus, NACshows promise as a potential therapeutic agent in HD. Furthermore, our data suggest that NACmay also have broader
antidepressant efficacy.
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INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant neurode-
generative disorder resulting from an expanded CAG tandem
repeat in the gene encoding huntingtin (HTT).1 The mutant form
of HTT includes an expanded polyglutamine tract and elicits
progressive psychiatric, cognitive and motor symptoms. A primary
neuropathology associated with HD is the selective dysfunction,
and eventual death, of medium spiny neurons within the
striatum,2–4 although the cerebral cortex and other areas are also
affected. The exact cause of such cellular dysfunction is still
unclear, however, it is known that mitochondrial dysfunction,
oxidative stress and excitotoxicity have amajor role.5–8 The amino
acid, cysteine, has the potential to alleviate each of these features
of HD pathology. The compound N-acetylcysteine (NAC) is able to
cross the blood–brain barrier and directly donate cysteine to the
central nervous system, acting as a potential therapy.9
Oxidative stress has been shown to occur in the brain of
patients with HD,5,6 while an increase in peripheral reactive
oxygen species and markers of oxidative stress occur in those in
the prodromal phase of the disorder.10 Furthermore, transgenic
animal models expressing the amino (N)-terminal fragment of
mutant form of Htt show oxidative stressoccurring in the striatum
before the onset of motor symptoms.11 Cysteine is the rate-
limiting amino acid required for the synthesis of glutathione
(GSH), the primary endogenous antioxidant in the brain.12
Administration of NAC increases levels of GSH, reducing oxidative
stress.13 It has recently been shown that cysteine supplementation
is able to alleviate some of the pathology observed in animal
models of HD.14
NAC also has the capacity to modulate glutamate-induced
toxicity. The elevated synaptic glutamate observed in excitotoxic
states leads to dysregulated glutamate receptor activity. Evidence
supporting an excitotoxic mechanism in HD includes the
development of striatal medium spiny neuron degeneration
following the administration of the N-methyl-D-aspartate
antagonist, quinolinic acid.15 Furthermore, the R6/2 transgenic
mouse model of HD was found to show increased N-methyl-D-
aspartate activation before the onset of behavioral phenotypes,16
while the administration of N-methyl-D-aspartate antagonists
were found to delay the progression of symptoms in HD
patients.17,18 However, the question remains as to why there is
an increased glutamatergic signaling in HD. Astrocytic glutamate
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uptake may be reduced, leading to an increase in synaptic
glutamate. Supporting this, RNA and protein levels of the
astrocytic glutamate antiporter, GLT-1 are reduced in postmortem
brains of HD patients and transgenic mice.19,20 Furthermore,
treatment with the GLT-1 agonist, ceftriaxone, was found to
increase GLT-1 expression and decrease motor abnormalities in
the R6/2 mouse model.21 NAC can alleviate excess synaptic
glutamate by promoting astrocytic uptake.
Astrocytic glutamate transport can occur via several transpor-
ters, two of which are dependent on cysteine: Excitatory amino-
acid transporter-1 (also known as GLT-1), which is directly
dependent on cysteine and System xc− , which is dependent on
cystine derived from oxidized cysteine.22,23 Supplementation with
NAC can both decrease synaptic glutamate and increase
intracellular cysteine via these transporters.22,24,25 These actions
of NAC are therapeutic in models of addiction.26,27 Given the
ability of NAC to increase GSH production and potentially
decrease synaptic glutamate via GLT-1, there is the possibility of
treating two of the primary neuropathological features of HD:
excitotoxicity and oxidative stress. Therefore, the aim of the
current study is to test the therapeutic potential of NAC in HD
using the R6/1 transgenic mouse model.
MATERIALS AND METHODS
Mice
R6/1 transgenic hemizygote males28 were originally obtained from the
Jackson Laboratory (Bar Harbor, ME, USA) and bred with CBB6 (CBA~C57/
B6) F1 females to establish the R6/1 colony at the Florey Institute of
Neuroscience and Mental Health. After weaning, animals were group
housed (four mice per cagewith two of each genotype) and maintained on
a 12h light/dark cycle with access to food and water ad libitum. To avoid
any possible ‘litter effects’, we ensured that animals from each litter were
represented in each experimental condition using appropriate randomiza-
tion. Experimental animals were kept in open-top cages under standard
housing conditions. All the experimentswere performed on wild-type (WT)
and R6/1 (HD) mice in accordance with the guidelines of the Florey
Institute of Neuroscience and Mental Health Animal EthicsCommittee and
the National Health and Medical Research Council.
N-Acetylcysteine treatment
N-acetylcysteine (NAC) wasobtained from Astral Scientific (#AM0108). NAC
was prepared in clinical-grade saline (0.9%) at concentrations suitable for
dosing at 500mg kg−1 per day. Solutions were pH-matched to that of the
vehicle (saline). NAC or vehicle were injected intraperitoneally (1ml per
100g body weight) daily, beginning at 8 weeksof age and continuing until
the mice were culled at 17 weeks of age. NACand saline treatments were
allocated semi-randomly, stratified to ensure that there were no baseline
differences in body weight or rotarod performance between treatment
groups.
Behavioral analysis
Accelerating rotarod. A rotarod (Ugo Basile model 7650; Sandown
Scientific, Hampton, UK) was used as a measure of motor performance.
A detailed protocol has been described previously.29 Experimenters were
masked to both genotype and treatment.One day before the initial testing
phase,mice were acclimatized to the rod; they were allowed to walk at the
baseline speed for 2min before allowing the rod to accelerate to 20 r.p.m.
over 150s. If the mice fell off during this time, they were placed back on
the rod until the acclimatization period was complete.
Paw clasping. Mice were held by the tip of the tail against the edge of a
table to prevent swinging motion. The mice were observed for a period of
30s, with the highest clasping score occurring during this time being
recorded.Mice were scored on a five-point scale (from 0 to 4) as described
previously.30,31 A score of 0 indicated that no clasping was present,
whereas scores from 1 to 4 represented the number of paws clasping.
Scorers were masked to both genotype and treatment.
Digigait. Assessment of gait wasperformed using the Digigait automated
treadmill (Mouse Specifics, Boston, MA, USA). On the initial trial, mice were
placed inside a plexiglass container on top of a transparent treadmill
and allowed to habituate for 1min. For all time points, the speed of the
treadmill was increased incrementally from 0 to 15cm s− 1 over a period of
15s. Video of the mouse from underneath was then recorded until the
mouse ran without stopping for a period of 3 s. The contact of each paw
on the treadmill was automatically detected via the Digigait system.
Scorersmasked to treatment and genotype manually corrected any errors
made by the Digigait Software. The major parameters of gait to be
analyzed relate to either the ‘duration’ or ‘consistency’ of various stride
characteristics. The duration parameters include: total stride, stance, swing,
propulsion and brake time. The consistency characteristics include: gait
symmetry, paw overlap, paw positioning, stance width and the ataxia
coefficient.
Forced swim test. The forced swim test wasconducted at 12 weeksof age,
asdescribed previously.32 Total immobility timewasscored manually by an
experienced experimenter masked to both genotype and treatment.
Western blotting
Immediately after cervical dislocation, mice brains were dissected on ice
and snap frozen in liquid nitrogen, before being stored at −80 °C. Tissue
homogenates were prepared in Tris-lysis buffer containing EDTA, EGTA,
glycerol, triton-X100, sodium fluoride, sodium pyrophosphate,Na3VO4,DTT
and a protease inhibitor cocktail (Sigma, Castle Hill, NSW, Australia;
#p8340). Ribolyser was used at mid-strength for ~10s with one oscillation
per second. Samples were allowed to rest for 10min on ice before
centrifugation at 180000g for 25min at 4 °C. Supernatants were removed
and protein concentrationswere determined using BCA total protein assay
(Thermo, Scoresby, VIC, Australia; #3225). Acrylamide (12%) bis/tris gels
were precast and allowed to set at 4 °C overnight. Sample buffer was
added to the samples before being heated at 95 °C for 3min. Samples
were then run in tris-glycine buffer using the Bio-Rad (Gladesville, NSW,
Australia) MiniPROTEAN Tetra cell system. Gels were transferred to PVDF
membrane before being blocked for 1h in 5% BSA. Blots were washed
three times in TBST before incubation in primary antibodies overnight at
4 °C. Primary antibodies were diluted in TBST containing 5% BSA:
anti-GLT-1 (1:1000; Millipore, Bayswater, VIC, Australia; #ABN102); anti-
xCT (1:500; Abcam, Waterloo, NSW, Australia; #AB37185); and anti-β-actin
(1:1000; Cell Signaling Technology, Beverly, MA, USA; #8H10D10). The
following day, blots were washed three times in TBST, before being
incubated in IR secondary antibodies (1:5000; Li-Cor; Lincoln, NE, USA;
#926-3211 and #926-68020) for 1h at room temperature. Blots were once
again washed three times before being imaged in the Li-Cor Odyssey IR
detection system. Densitometry was carried out using the integrated
intensity value for each band. Analyses of the results were carried out as
ratio of protein-of-interest:β-actin.
HPLC
Immediately after cervical dislocation, mice brains were dissected on ice
and snap frozen in liquid nitrogen, before being stored at −80 °C. Tissue
homogenates were prepared in 0.1% formic acid using a motorized latex
pestle for 10s with one oscillation per second. Samples were then
centrifuged at 8000g for 15min. The supernatants were then collected
and analyzed for levels of reduced and oxidized glutathione (GSH and
GSSG, respectively) using the method previously described.33
Protein carbonyl content
Protein carbonyl content was assayed using the Oxyblot kit (Millipore,
#S7150). Mitochondrial and nuclear fractions were separated as described
previously.34 Nuclear fractions were then prepared in lysis buffer, similarly
to whole tissue (see above), while mitochondria were prepared in the
mitochondrial isolation buffer. Total protein content was assayed before
the preparation of samples. 2,4-Dinitrophenylhydrazine was added to
samples to derivatize carbonyl groups from the protein side chains.
Derivatized samples were then separated using electrophoresis, as
described above. Western blot analysis was carried out, as described
above, using the 2,4-dinitrophenylhydrazine antibody provided (1:150).
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Densitometry was carried out using the integrated intensity value for each
band. Analyses of results were carried out as ratio of protein-of-interest:β-
actin. Given the presence of multiple bands, the average value of all bands
within each lane was used to give an overall measure of protein carbonyl
content.
Mitochondrial stress test
All bioenergetic and mitochondrial function analyses were performed
using the Seahorse XF24 Extracellular Flux Analyzer (Seahorse Bioscience,
Billerica, MA, USA). Immediately after cervical dislocation, the brain was
removed and dissected on ice. Sampleswere then finely chopped in buffer
containing mannitol (200mM), sucrose (50mM), KH2PO4 (5mM), EGTA (1
mM), MOPS(5mM) and BSA (0.1%) to aid in preserving mitochondria. The
tissue was then resuspended in the same buffer containing dimethyl
sulfoxide (20%), before being slowly frozen on dry ice and stored at − 80 °C.
Tissue was allowed to defrost on ice before mitochondria were isolated as
described previously.34 Mitochondria were then seeded on to 24-well
Seahorse V7 plates. Mitochondrial function was determined as previously
described35 and basal respiration (state II), adenine diphosphate (ADP)-
supplemented respiration with saturated substrate succinate (state III),
ADP-deprived respiration (state IV) and respiratory control rate (state III:
state IV ratio) were determined from these analyses. Each sample was
measured in triplicate, with average values taken from successful wells.
Successful wells were those that acted functionally by displaying normal
responses to oligomycin (decreased oxygen consumption rate), FCCP
(increased oxygen consumption rate) and antimycin A (complete shut-
down of oxygen consumption rate). This frozen mitochondria protocol was
validated by directly comparing freeze–thaw samples to fresh mitochon-
drial samples on the same plate. No differences in mitochondrial
respiration were found (data not shown).
Statistics
Statistical analyses were performed using IBM SPSSstatistics Version 21.0
(IBM, Armonk, NY, USA) and GraphPad Prism 6 (GraphPad Software, La
Jolla, CA, USA). Rotarod, clasping, Digigait and body weight data were
analyzed using three-way repeated measures analysis of variance. If
Figure 1. Treatment with NACdelays the onset and progression of motor deficits in HD mice and has antidepressant-like effects in both HD
and WTmice. (a) Analysis of the clasping phenotype showed a significant age× treatment × genotype interaction. Post hoc analyses revealed
that NAC significantly delayed the onset of the clasping phenotype in HD mice, with saline-HD mice showing clasping behavior from
10 weeks onward, while NAC-HD mice did not show clasping behavior until 14 weeks. NAC-treated HD mice also showed significantly lower
levelsof clasping behavior relative to saline-treated HDmice from 11 weeksonward. (b) A significant age× treatment interaction was found in
Rotarod. Post hoc analyses revealed that the treatment effect began at 12 weeks of age, with NAC-HD mice performing better than saline-HD
mice from 11 weeks of age. There was also a significant age× genotype interaction, with post hoc analyses revealing that genotype deficits
were present from 8 weeks of age, progressively worsening over the lifespan of the mice. (c) Representation of the different phases of stride
that can be measured using the Digigait, including total stride, stance, swing, brake and propel duration. (d) A significant
treatment × genotype interaction was found in the propel/brake ratio. Post hoc tests show that saline-HD mice have a higher ratio than
both NAC-HD and saline-WT mice. (e) A significant treatment effect was seen in the time spent immobile during the FST, with NAC-treated
mice spending less time immobile than saline-treated mice. Error bars represent mean ± s.e.m.; n= 10–14; treatment effects: *Po 0.05,
**Po 0.01, ***Po 0.001. FST, forced swim test; HD, Huntington’s disease; NAC, N-acetylcysteine; WT, wild type.
NAC improves function in an HD model
DJWright et al
3
Translational Psychiatry (2015), 1–10
sphericity was violated, Greenhouse–Geisser corrections were used. If
significant interactions were found, alpha-levels for post hoc comparisons
were corrected using Bonferroni’s method. All other data were analyzed
using two-way analyses of variance. Alpha levels for post hoc comparisons
were corrected using Tukey’s honestly significant difference. In all the
cases, significance was set at Po 0.05.
RESULTS
NACdelays the onset and slows the progression of motor deficits
Paw clasping is a primary motor endophenotype that is observed
in the R6 transgenic models of HD.28 A significant interaction of
age, treatment and genotype was found on the development of
the clasping phenotype (F(9,35)= 4.268, P= 0.001; Figure 1a). Post
hoc analyses revealed that NACsignificantly delayed the onset of
the clasping phenotype in HDmice. Specifically, saline-treated HD
mice differed from control mice from 10 weeks (P= 0.017),
whereas NAC-treated HD mice did not differ from controls until
14 weeks (P= 0.030). Furthermore, NAC-treated HD mice per-
formed significantly better than saline-treated HD mice from
11 weeks (P= 0.003) onward, showing reduced clasping scores
until the final data point of 17 weeks (Po 0.001).
The Rotarod was also used to assess motor coordination, and
revealed a significant interaction of age and genotype (F
(9,35)= 7.993, Po 0.001). Post hoc analyses revealed that HD mice
displayed rotarod deficits from baseline (8 weeks; P= 0.001) and
progressively worsened until 17 weeks (Po 0.001). However, a
significant interaction of treatment and age was also observed (F
(9,35)= 2.746, P= 0.015; Figure 1b). Post hoc analyses show that
NAC-treated HD mice performed better than saline-treated HD
mice from 11 weeks (P= 0.038) of age onward.
In a separate analysis of the lower dose of 250mg kg−1 per day
(data not shown), a significant age× genotype interaction wasalso
found (F(7,33)= 6.191, Po 0.001), with the HD mice showing
deficits by 10 weeks (P= 0.012) and progressively worsening until
17 weeks (Po 0.001). A significant main effect of treatment was
also seen at the lower dose (F(1,39)= 4.974, P= 0.039).
NAC rescues gait abnormalities
The Digigait behavioral apparatus was used to assess if NAC
rescues gait abnormalities present in R6/1 mice. Mice were
assessed at 8, 10, 12 and 14 weeks of age. Later time points were
not measured asHDmice were unable to perform the task due to
the progressive degeneration. The session conducted at the 8-
week time point was taken asa training session, so measurements
were not included in the end analysis. At this time point all groups
show movement patterns that are consistent with a motor
learning phase (Supplementary Figures 1a and b). Overall, the
duration of each phase of movement of the hind pawswere found
to be the more sensitive indicators of gait abnormalities in HD
mice, therefore, the following data are specific to hind paws only.
The time spent in each phase of the stride can be broken down
into the following: total stride, stance, swing, propulsion and brake
time (as shown in Figure 1c). Significant interactions between age
and genotype are present in stride, stance and swing duration (F
(2,34)= 7.841, P= 0.002; F(2,34)= 5.918, P= 0.006; F(2,34)= 4.941,
P= 0.010; Supplementary Figures 1d and f). Post hoc tests reveal
that for each parameter, measurements for WT mice increased
from 12 to 14 weeks (P= 0.027; P= 0.016; and P=0.027,
respectively), while HD mice decreased in stride duration from
12 to 14 weeks (P= 0.022). Within stance, no changes were found
in the time spent propelling (data not shown), whereas a
significant interaction of treatment and genotype was found in
the time spent braking (F(1,35)= 9.728, P= 0.004; Supplementary
Figure 1c). Post hoc comparisons revealed that saline-treated HD
mice had lower braking time than controls (P= 0.014), whereas
NAC-treated HDmice showed no differences relative to controls. A
significant interaction of age and genotype was also found (F
(2,34)= 4.399; P= 0.010), with HD mice showing decreased brake
duration at 14weeks (P= 0.012), but no difference at 10–12 weeks.
A significant interaction of treatment and genotype was found in
the propel/brake ratio (F(1,35)= 9.841, P= 0.003; Figure 1d). Post
hoc tests revealed that saline-treated HD mice show an increased
ratio compared with both NAC-treated HD mice (P= 0.046) and
controls (P=0.002), whereas NAC-treated HD mice showed no
difference to controls. No changes were found in gait symmetry,
paw overlap, paw positioning, stance width and the ataxia
coefficient (data not shown).
NAC reduces immobility during forced swim
The time spent immobile during a period of forced swim wasused
as a measure of learned helplessness. No differences were found
between genotypes. However, a significant effect of treatment
was found (F(1,44)= 5.739, P= 0.021), with NAC-treated mice
having lower immobility time than saline-treated mice
(Figure 1e). This effect was replicated at a lower dose of 250
mg kg−1 (F(1,23)= 5.992, P= 0.022), with NAC-treated mice having
lower immobility time than saline-treated mice (data not shown).
Change in brain weight, but not body weight, is rescued by NAC
A significant interaction of genotype and treatment was found in
brain weight (F(1,43)= 9.428; P= 0.004). NAC-treated HD mice
were found to have heavier brains than saline-treated HD mice
(Po 0.001), whereas both WT mice had heavier brains than both
saline and NAC-treated HD mice (Po 0.001 for each comparison;
Figure2. NACaffectsbrain weight but not body weight of R6/1mice. (a) A significant interaction between genotype and treatment was found
in the brain weight of 17-week-old mice. Post hoc analyses revealed that saline-treated HDmice had significantly lower brain weights than WT
mice, and NACpartially restored this. (b) A significant age× genotype interaction was found in body weight. Post hoc tests revealed that the
genotype difference began at 12 weeks of age and progressively increased until 17 weeks. Error bars represent mean ± s.e.m.; n= 10–14;
treatment effects: ***Po 0.001. HD, Huntington’s disease; NAC, N-acetylcysteine; WT, wild type.
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Figure 2a). A significant interaction of age and genotype was
found (F(9,35)= 16.763; Po 0.001), with body weights of HD mice
declining from 13 weeks (Figure 2b). However, no differences
were noted due to treatment.
NACdoes not affect glutamate transporters
Western blot analysis was carried out on striatal and cortical
samples from 17-week-old mice. GLT-1 levels were found to be
reduced in the striatum and cortex of HD mice (F(1,24)= 6.032,
P= 0.029; and F(1,24)= 15.03, Po 0.001, respectively), however,
this deficit was not rescued by NAC (Figures 3a and b). The light
chain of System xc− , denoted xCT, confers substrate specificity,36
hence, protein levels of xCTwere measured as an index of System
xc− expression (Figures 3c and d). No changes in xCTwere found
across genotype or treatment groups in either the striatum or
cortex.
NAChas mitochondria-specific antioxidant effects
GSH is one of the primary endogenous antioxidants. When GSH is
oxidized, it forms glutathione disulfide (GSSG). By looking
at the ratio of GSH:GSSG, the antioxidant capacity of the cell can
be inferred.9 To assess the antioxidant capacity of the striatum,
GSH and GSSG were measured via HPLC. No changes in either
GSH, GSSG or the GSH:GSSG ratio were found (Supplementary
Figure 2).
As the effects of oxidative stress may differ across cellular
compartments, the striatal tissue of 17-week-old mice was
separated into mitochondrial and nuclear fractions. Protein
carbonylation is a stable indicator of oxidative damage to
proteins.37 Within the nuclear fraction of the striatum, no
difference in protein carbonylation was found within either
genotype or treatment groups (Figure 4b). In contrast, the analysis
of protein carbonylation in striatal mitochondria revealed a
significant interaction between genotype and treatment (F
(1,26)= 8.864, P= 0.006; Figure 5a). Post hoc comparisons show
that there is a two-fold increase in protein oxidation in HD mice
(Po 0.01), which NAC is able to completely rescue (Po 0.05). No
differences in protein carbonylation were found between the
treatment or genotype groups, in either the nuclear or mitochon-
drial fraction of cortical tissue (Figures 4c and d).
NAC rescues functional deficits in HD mitochondria
Mitochondria were isolated from the striatum and cortex and a
mitochondrial stress test was performed to assess their function.
Mitochondria isolated from the striatum show differences in state
II, state III and state IV respiration, and the state III:state II ratio
(Figure 5a). Specifically, a significant interaction was found in state
Figure3. Western blot analysisof astrocytic glutamate transporter proteins in the striatum and cortex. (a–b) GLT-1 wassignificantly reduced in
the striatum and cortex of HD mice, but was unaffected by NAC treatment. (c–d) Protein levels of xCTwere unchanged across genotype and
treatment. Error bars represent mean ± s.e.m.; n= 7–8; genotype effects: #Po 0.05. HD, Huntington’s disease; NAC, N-acetylcysteine; WT,
wild type.
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II respiration (F(1,18)= 8.078, P= 0.011), with post hoc tests
revealing that saline-treated HD mitochondria had lower state II
respiration than saline-treated WT mitochondria (Po 0.05). A
significant interaction was also found in state III and state IV
respiration (F(1,18)= 9.409, P= 0.007; and F= 6.738, P= 0.018,
respectively), with post hoc tests revealing that saline-treated HD
mitochondria had lower state III and state IV respiration than
saline-treated WT mitochondria (Po 0.05). Furthermore, a geno-
type effect was found on the state III:state II ratio (F(1,18)= 10.85,
P= 0.004), with HD mitochondria showing a higher ratio than WT.
No changes were found in the respiratory control rate. Mitochon-
dria isolated from the cortex show no differencesacross treatment
or genotype groups on any measures of respiration (Figures 2g
and l).
DISCUSSION
Motor dysfunction is a primary clinical symptom of HD. In this
study, we show that NAC is able to delay the onset, and slow the
progression, of motor symptoms in a transgenic mouse model of
HD. Depressive symptomsare also common in HD38 and we show
that NAC displays antidepressant-like effects in both HD and WT
mice. NAC was found to rescue oxidative stress within striatal
mitochondria of HD mice. These changes were associated with
rescued functional deficits in the mitochondria. This supports the
hypothesis that NAC rescues motor dysfunction by ameliorating
mitochondrial dysfunction and inhibiting oxidative stress.
We have employed a comprehensive analysis of R6/1 motor
deficits to assess the domains that are rescued by NAC.
Uncontrolled and reflexive paw-clasping is a primary motor
endophenotype shown by the R6 transgenic mice.28 NAC was
able to substantially delay the onset of paw-clasping in HD mice,
and significantly reduce the severity of this abnormal phenotype.
Similar effects were also seen in rotarod performance.
The rotarod is the most widely used tool to test motor
performance in HD mice. The rotarod primarily tests locomotor
coordination, with R6/1 mice displaying a progressive deficit in
their performance.39 R6/1 mice were treated with NAC after the
onset of this deficit; however, the drug was still able to
significantly inhibit the progressive loss of locomotor coordina-
tion. It is striking that NACwas able to take effect even in animals
that had already undergone some loss of striatal function. In
contrast, NAC has been shown previously to have detrimental
effects in fly and zebrafish models of HD40 when administered
before the development of HD phenotypes. Thiswas shown to be
due to an inhibition of autophagy clearance of mutant HTT
aggregates. It may be that the therapeutic benefit of NAC
outweighs possible detriments after the pathological hallmarks
have developed,41 although it is difficult to directly compare
dosing regimes across such divergent model species. Similar
dichotomous effects have also been seen in HD models using
other paradigms such as stress, where corticosterone treatment
was found to hasten the onset of cognitive symptoms in
presymptomatic R6/1mice42 whereasdexamethasone (a synthetic
glucocorticoid) administration was able to increase heat-shock
response, reduce mutant HTT aggregate load and slow the
progression of motor dysfunction in the more severe R6/2 model
of HD.43 Furthermore, evidence for the therapeutic effects of NAC
in HD mice expressing a human transgene is likely to be more
clinically relevant than the data from transgenic fish and flies.
Thus, NAChas advantages for potential clinical application of this
therapy, where diagnosis and treatment are typically commenced
after the development of analogous motor symptoms.
The therapeutic effects of NAC were also mirrored in the gait
analysis of R6/1 mice. The Digigait analysis has only been
published once previously in a HD mouse model, in which Pallier
et al.44 conducted a cross-sectional analysis of gait in late-stage
R6/2 mice (17 weeks). We are the first to report a progressive
analysis of gait in a HD animal model, beginning at the time of
motor symptom onset. Overall, R6/1 mice show an emerging
deficit in two components of stance: time spent braking and the
brake-to-propel ratio. Specifically, HD mice display a decrease in
the time spent braking, with a subsequent increase in the propel-
to-brake ratio. These findings are consistent with Pallier et al., who
Figure 4. Oxidative stress as assayed by protein carbonyl content in fractions of striatal and cortical tissue. (a) There was a significant
interaction between genotype and treatment in protein carbonyl content within the striatal mitochondria. Post hoc comparisons revealed that
saline-HD mitochondria had higher protein carbonyl content than saline-WT and this was rescued in NAC-HD mice. (b–d) There were no
differences in protein carbonyl content in the mitochondrial fraction of the cortex, or in the nuclear fractions from the striatum and cortex
across either genotype or treatment groups. Error bars represent mean ± s.e.m.; n= 7–8; genotype and treatment effects: ##Po 0.01 and
*Po 0.05, respectively. HD, Huntington’s disease; NAC, N-acetylcysteine; WT, wild type.
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found deficits within ‘stance’ components only. Importantly, we
found that NACwas able to rescue these deficits. Thus, with the
treatment of NAC, we were able to rescue deficits in R6/1 mice
from three separate domains of motor function: reflexive paw-
clasping, locomotor coordination and gait. NAC also had
antidepressant-like effects.
Depression is the highest occurring psychiatric comorbidity in
HD,38 with recent studies suggesting that it is an inherent
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symptom of the disorder.45 Immobility time during the forced
swim test is the gold standard for screening the efficacy of
antidepressants in rodents.46 We found that NAC was able to
reduce the time spent immobile in both R6/1 mice and their
wild-type littermates. This has implications for both HD and wider
research on major depression, suggesting that NAC may be an
effective antidepressant. This supports data from previous
clinical studies on bipolar patients, which have shown NAC to
have positive effects on the depressive symptoms of the
disorder.47 Taken together, NAC was able to display
antidepressant-like effects, while also rescuing an array of motor
deficits in the R6/1 mice. Our findings are echoed by a recent
publication displaying the ability of cysteine supplementation to
reverse clasping and Rotarod deficitswithin the R6/2 model of HD
—although gait and affective-like behaviors were not assessed.14
In this study, cysteine supplementation was given using a
cysteine-rich diet in combination with NAC. Our study is the first
to display the therapeutic effect of NAC alone in a transgenic
animal model.
NAC may be acting in the brain through modulation of
glutamatergic excitotoxicity or levels of oxidative stress.
Glutamate-dependent toxicity is an established mechanism of
cellular dysfunction within both HD patients and animal
models.7,48–50 Glutamate can be transported out of the synapse
by a variety of excitatory amino-acid transporters, including the
astrocytic transporter, GLT-1.24 GLT-1-dependent glutamate
uptake is impeded by the presence of a high extracellular
glutamate-to-cysteine ratio.24,25 Therefore, the increase in synaptic
glutamate may explain why GLT-1 is decreased in HD.19,20,51 Our
findings replicate previous studies19,52 showing a deficit in striatal
and cortical GLT-1, however, NAC did not rescue this change.
NAC is also capable of acting on a second astrocytic glutamate
transporter, System xc− .23 System xc− is responsible for the
transport of glutamate from astrocytes in a 1:1 exchange for
extracellular cysteine.22,53 Cystine is produced by creating a
disulfide bond through the oxidation of two cysteine groups,
and is thus dependent on extracellular levels of cysteine.24
Previous studies have shown that NAC is able to upregulate
glutamate–cysteine exchange, and this has a therapeutic effect in
treating drug withdrawal in animals and humans.26,54 The light
chain of System xc− , xCT, confers substrate specificity, thus
protein levelsof xCTwere analyzed to evaluate functional changes
in System xc− . No changes were found in levels of xCT.
Considering GLT-1 and System xc− are the only glutamate
transporters dependent on the presence of extracellular cysteine,
we can conclude that the mechanism of action of NAC in R6/1
mice is not directly related to the reduction of glutamate-
dependent toxicity. We, therefore, hypothesized that NAC is
functioning by reducing oxidative stress.
GSH is the primary endogenous antioxidant.55 When GSH is
oxidized, it formsGSSG.55 By looking at the ratio of GSH:GSSG, the
antioxidant capacity of the cell can be inferred.9 Previous studies
in HD have shown that GSH is reduced in the serum of HD
patients.10 However, other studieshave shown that GSHand GSSG
are unchanged in R6/1 mouse striatum at the onset of motor
symptoms.33 NAC could potentially stabilize the GSH:GSSG
balance by donating cysteine for the synthesis of new GSH.56
We observed no changes in either GSH, GSSG or the GSH:GSSG
ratio in unfractionated tissue homogenates. However, the levelsof
these key elements of the antioxidant system are differentially
regulated across cellular organelles.
GSH is produced in the cytosol and transferred to other
intracellular components, such as nuclei and mitochondria.57,58
Thus, although the total GSH/GSSG pools may be unchanged at
the level of the whole tissue, it may be that oxidative stress is
occurring in specific organelles of the cell. To investigate the
possibility of compartmentalized oxidative stress, the striatal and
cortical tissue of 17-week-old mice were fractionated into
mitochondrial and nuclear components. Given the volatile nature
of the GSH-GSSGredox cycle, aswell as the reactive nature of GSH
to oxidation, it may be that subtle differences in GSH:GSSG are
quickly lost in the postmortem brain.59 Therefore, protein
carbonylation wasassessed asamore stable indicator of oxidative
damage to proteins.37 It was found that thiskey marker of damage
resulting from oxidative stresswas increased in mitochondrial, but
not nuclear, fractions of striatal tissue only. Importantly, NACwas
able to rescue this region- and organelle-specific oxidative stress.
It hasbeen shown previously that mitochondria aremore prone
to oxidative damage than nuclei within immortalized striatal cells
from HdhQ111/Q111 mice.60 This is to be expected given that
mitochondria are the primary source of reactive oxygen species
within the cell.61 Mitochondria are more likely to leak reactive
oxygen species when they are not functioning efficiently.61
Multiple studies have shown mitochondrial processes to be
dysfunctional in HD, including reductions in the activity of
electron transport chain complexes II, III and IV,6,48,62,63 as well
as reduced activity of aconitase,50 pyruvate dehydrogenase64 and
creatine kinase.65 Each of these studies are beneficial in showing
reductions in activity of specific enzymes, however, the electron
transport chain containsdynamic protein complexes, and isolation
of specific enzymes cannot elucidate the overall mitochondrial
function. Thus, we sought to look at the respiratory function of
intact mitochondria isolated from the striatum of R6/1 mice. We
hypothesized that the oxidative stress specific to the R6/1
mitochondria would be associated with an overall reduction in
mitochondrial oxidative metabolism, which would be rescued by
NAC treatment.
To assess mitochondrial function, oxygen consumption rates
were assessed after the administration of various mitochondrial
substratesand inhibitors. Thisanalysisshowed that NACenhanced
baseline respiration (state II), maximal ADP-stimulated respiration
(state III) and respiration after consumption of ADP(state IV), in HD
mice, suggesting that NACcould enhance mitochondrial capacity
in this model. This provides functional evidence to support the
finding that ATPpools are depleted in HD models.66 This also has
potential implications for the generation of mitochondrial reactive
oxygen species, a putative pathogenic factor in HD. Lower
capacity for ADP-stimulated respiration, in the face of constant
energy demand and substrate supply, increases themitochondrial
membrane potential. Electron leak from the respiratory chain in
the form of O2− is a compensatory response to limit further
increases in membrane potential, resulting in an oxidative stress
response.67 Indeed, the enhanced respiratory capacity of HDmice
treated with NACwasassociated with lower protein carbonylation
Figure5. Functional analysis of mitochondria isolated from the striatum and cortex. (a) Overview of the results from the mitochondrial stress
test performed on the striatal mitochondria, where it was found that: (b–d) State II, state III and state IV respiration, all displayed significant
interactions. Post hoc tests all showed that saline-HD mitochondria had lower respiration than saline-WT. NAC-HD mitochondria did not differ
from saline-WT mitochondria in any respiratory state. (e) A significant genotype effect was found in the state III:state II ratio, with HD
mitochondria higher than WT. (f) No differences in RCR were found in the striatal mitochondria. (g) Overview of the results from the
mitochondrial stress test performed on the cortical mitochondria, where it was found that: (h–l) state II, state III and state IV respiration, the
state III:state II ratio and RCR, did not differ between groups. Error bars represent mean ± s.e.m.; n= 7–8; genotype effects: *Po 0.05; ##Po 0.01.
HD, Huntington’s disease; NAC, N-acetylcysteine; RCR, respiratory control rate; WT, wild type.
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in mitochondrial fractions from HDmice and could have protected
from further mitochondrial oxidative damage and dysfunction.
Taken together, NAC was found to delay the onset and
progression of motor dysfunction in the R6/1 transgenic mouse
model of HD, while displaying antidepressant-like effects on both
R6/1 and WTmice. NACwas also shown to rescue mitochondrial
dysfunction and reduce oxidative stress within the R6/1 striatum,
identifying a likely mechanism of action. Considering that NAC is
established as safe for clinical use,68 our data suggest that it
should be considered asa candidate for trial aseither a primary or
adjunctive treatment for symptomatic HD patients. The question
of whether NAC would be effective in presymptomatic stages of
the disease is also a high priority for investigation, and it is
suggested that trialing NACon a slower progressing model, such
as knock-in or BACHD mice, would provide more insight, as there
are no disease-modifying therapies currently available for this
devastating disorder.
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